Your session is about to expire
← Back to Search
Epcoritamab Combinations for Non-Hodgkin's Lymphoma (EPCORE™ NHL-2 Trial)
EPCORE™ NHL-2 Trial Summary
This trial is testing a new drug, epcoritamab, to see if it is safe and effective in treating B-cell Non-Hodgkin Lymphoma.
EPCORE™ NHL-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEPCORE™ NHL-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EPCORE™ NHL-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My neuropathy is mild or I don't have it.My lymphoma is CD20-positive.I am on medication for my seizure disorder.I have had a stem cell transplant from a donor.I am a man willing to use contraception if my partner can have children.I am currently taking medication to boost my immune system.My lymphoma has spread to my brain, confirmed by scans and possibly a lumbar puncture.I can take care of myself and am up and about more than half of the day.I have a serious heart condition.I have at least one tumor that can be measured on a scan.I have been treated with a medicine that targets both CD3 and CD20.I have tested positive for HIV.I have active tuberculosis or finished treatment for it within the last year.I do not have any major health issues that could interfere with the study.I haven't had chemotherapy, radiation, or major surgery in the last 4 weeks.My organs are functioning well.I have not had CAR-T therapy in the last 30 days.
- Group 1: Arm 9 - Epcoritamab + Lenalidomide
- Group 2: Arm 10 - Epcoritamab + R-ICE
- Group 3: Arm 1 - Epcoritamab + R-CHOP
- Group 4: Arm 2 - Epcoritamab + R2
- Group 5: Arm 3 - Epcoritamab + BR
- Group 6: Arm 4 - Epcoritamab + R-DHAX/C
- Group 7: Arm 5 - Epcoritamab + GemOx
- Group 8: Arm 6 - Epcoritamab + R2
- Group 9: Arm 7 - Epcoritamab maintenance
- Group 10: Arm 8 - Epcoritamab + R mini-CHOP
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 30 Other Conditions - This treatment demonstrated efficacy for 30 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have been recruited for this clinical trial?
"The AbbVie-sponsored study requires 396 qualified participants, and will be conducted at the John Theurer Cancer Center in Hackensack, New jersey as well as UMPC Hillman Cancer Center in Pittsburgh, Pennsylvania."
Are there still vacancies in this clinical trial?
"According to clinicaltrials.gov, the current state of affairs shows that this trial is actively seeking participants; it was first posted on November 16th 2020 and edited most recently on April 13th 2022."
How many centers are conducting this research trial?
"Patients interested in participating can find locations for this clinical trial at the John Theurer Cancer Center, Hackensack UMC (Hackensack NJ), UMPC Hillman Cancer Center cancer Pavillion (Pittsburgh pa) and Dana Farber Cancer Institute (Boston ma). 10 other sites are also available."
What medical conditions are commonly addressed with rituximab and lenalidomide?
"Rituximab and lenalidomide are typically used to treat macular edema, as well as pheochromocytomas, ocular conditions, and ulcerative colitis."
Are there any prior investigations that have combined rituximab and lenalidomide?
"Rituximab and lenalidomide were first studied at the NIH Clinical Centre on Rockville Pike back in 1993. To date, there have been 5624 studies that have concluded with 3255 presently ongoing; a substantial amount of these trials are taking place out of Hackensack, New jersey."
Share this study with friends
Copy Link
Messenger